Analyst Upgrades

• Applied Materials (AMAT) to overweight from neutral at Piper Jaffray.
• Air Products (APD) to buy from hold at Citigroup.
• Youku.com (YOKU) and Pinnacle West (PNW) to buy from neutral at Goldman.
• Stryker (SYK) and Zimmer (ZMH) to buy from neutral at UBS.
• Zions Bancorp (ZION) to outperform from neutral at Macquarie.
• Alnylam (ALNY) to buy from hold at Needham.
• AK Steel (AKS) to buy from hold at KeyBanc.

Analyst Calls

• Medtronic (MDT) to buy from neutral and 1-800-Flowers.com (FLWS) to neutral from sell at Goldman.
• CarMax (KMX) to outperform from perform at Oppenheimer.
• Points International (PTSEF) to buy from neutral at Merriman.
• Nokia (NOK) to market perform from underperform at Morgan Keegan.
• Amdocs (DOX) to overweight from equal weight at Barclays.
• Western Alliance (WAL) to outperform from sector perform at RBC Capital.
• Carbo Ceramics (CRR) to outperform from market perform at BMO Capital.
• Rackspace (RAX) to buy from hold at Benchmark Co.
• Brinker (EAT) to equal weight from underweight at Morgan Stanley.

"Myriad Genetics (MYGN) is an innovative company that can diagnose your risk of cancer years before you have any symptoms," notes growth stock expert Lou Basenese.

The editor of White Cap Research explains, "Even better, it benefits from no competition and one of the best research and development teams around.

"Myriad Genetics' main product is called BRACAnalysis, which is a test that analyzes a woman's genetics to determine her likelihood of developing breast and ovarian cancers. Plain and simple, the test saves lives ... and money.

Analyst Upgrades

• Piper Jaffray upgraded Duoyuan Global Water (DGW) to neutral from underweight, citing the potential for positive fundamental news flow through the end of the year, and upped its price target to $16 from $9.
• Jefferies upgraded Alcatel-Lucent (ALU) to buy from underperform, expecting a benefit from a significant ramp in EVDO software sales as mobile data growth accelerates.
• Myriad Genetics (MYGN) was upgraded at RBC Capital to outperform from sector perform with a $23 price target based on valuation and potential to be acquired.
• Goldman upgraded Mohawk (MHK) to neutral from sell with a $53 price target.
• Smithfield Foods (SFD) was upgraded to outperform from market perform at BMO capital with a $21 target.
• Priceline.com (PCLN) was upgraded to outperform from market perform at Morgan Keegan.

Analyst Upgrades

• JPMorgan upgraded Norfolk Southern (NSC) to overweight from neutral, citing the company's leverage to coal and position relative to peers. The firm has a $68 price target for shares.
• Benchmark upgraded Royal Dutch Shell (RDS.A) to hold from sell based on a more favorable earnings outlook and reduced dividend risk.
• UBS upgraded Costco (COST) to buy from neutral based on valuation. The firm raised its price target to $63 from $62.
• Visa (V) was upgraded to gonviction buy from buy at Goldman.
• KLA-Tencor (KLAC) was upgraded to outperform from neutral at Credit Suisse.
• Texas Instruments (TXN) was upgraded to outperform from perform at Oppenheimer.

Here are some highlights from this past week's earnings coverage on BloggingStocks:

• American International Group Inc. (AIG) said its Q1 earnings doubled, easily topping analysts' expectations.
• Cablevision Systems Corp. (CVC) said Q1 revenue grew, but disappointing earnings dragged down shares.
• Chevron Corp. (CVX) had strong Q1 earnings and boosted its dividend, but Gulf spill concerns weighed on shares.
• CVS Caremark Corp. (CVS) Q1 earnings topped consensus estimates but it also said same-store sales slipped.
• Freddie Mac (FRE) said its lost $8 billion in Q1, less than a year ago, and requested further bailout funds.

Tuesday, Myriad Genetics (MYGN) announced weaker-than-expected quarterly sales and forecast full-year earnings below the expected $1.50 per share and revenue well below the expected $382 million.

Wednesday, the stock felt the ire of spurned investors and disgruntled brokerages. MYGN is more than 25% lower as a four brokerages (at last count) cut their ratings on the firm.

Analyst Upgrades

• Citigroup upgraded Baker Hughes (BHI) to hold from sell following the company's Q1 results.
• Auriga upgraded Canadian Solar (CSIQ) to buy from hold as it believes the company's negative preannouncement on April 20 removes a downside catalyst. Despite upgrading, the firm lowered its target for shares to $21 from $25.
• Deutsche Bank upgraded Post Properties (PPS) to hold from sell following the company's Q1 results. The firm upped its target for shares to $27 from $16.
• Wright Express (WXS) was upgraded to buy from neutral at Goldman.
• Nvidia (NVDA) coverage was assumed with a buy from hold at ThinkEquity.
• Elan (ELN) was upgraded to neutral from sell at UBS.

Myriad Genetics (MYGN) stock is trading lower today after a Federal District Court ruled that the company's claims covering isolated DNA sequences in seven of the 23 patents covering BRACAnalysis are invalid. The company said it will appeal the decision. If you think this stock won't be rising too far in the coming months, then it could be a good time to look at a bearish hedged play on MYGN.

This morning, MYGN opened at $23.86. So far today the stock has hit a high of $24.00 and a low of $23.07. As of 11:55, MYGN is trading at $23.63, down $1.27 (-5.1%). The chart for MYGN looks bullish.

Analyst Upgrades

• JPMorgan upgraded TiVo (TIVO) to overweight from neutral as it believes Thursday's appeal win against DISH Network could lead to revenue upside. The firm raised its target price for shares to $23 from $15.
• Collins Stewart upgraded DISH Network (DISH) to buy from hold on valuation, as it believes much of the impact from the negative appeals ruling is priced into the stock. The firm has a $30 target for shares.
• Cowen upgraded Ciena (CIEN) to outperform from neutral. The firm believes Ciena's acquisition of MEN is transformative and will accelerate top line growth.
• Progress Software (PRGS) was upgraded to buy from hold at Needham.
• Allergan (AGN) was upgraded to buy from hold at Lazard Capital.
• Public Service (PEG) was upgraded to buy from hold at Jefferies.

Analyst Upgrades

• FBR Capital upgraded MicroStrategy (MSTR) to outperform from market perform after channel checks indicated MicroStrategy 9 product cycle's continued to gain momentum in Q4. The firm raised its target price on shares to $120 from $87.
• Following a management meeting, Baird upgraded Woodward Governor (WGOV) to outperform from neutral based on long-term energy control growth opportunities and low Street expectations. The firm raised its target to $33 from $24.
• Citigroup upgraded Under Armour (UA) to hold from sell as it believes the company's initiatives in footwear will accelerate growth and share downside is limited at current levels. The firm raised its target on shares to $31 from $24.
• Procter & Gamble (PG) was upgraded to buy from neutral at BofA/Merrill.
• Aflac (AFL) was upgraded to equal weight from underweight at Barclays.
• MGM Mirage (MGM) was raised to buy from neutral at Goldman.

Analyst upgrades:

• FBR Capital upgraded U.S. Bancorp (NYSE: USB) and New York Community Bancorp (NYSE: NYB) to Market Perform from Underperform to reflect a new valuation framework. The firm raised its target on U.S. Bancorp to $21 from $14 and on New York Community Bancorp to $10 from $9.
• Stephens upgraded Insulet (NASDAQ: PODD) to Overweight from Equal Weight to reflect the company's top-line growth prospects and reasonable expectations. The firm raised its target on shares to $14 from $8.
• Baird upgraded Athenahealth (NASDAQ: ATHN) to Outperform from Neutral and raised its target to $46 from $37 based on expectations for revenue and gross margin expansion, and relative valuation.
• Broadcom (NASDAQ: BRCM) was upgraded to Overweight from Equal Weight at Barclays.
• Phillips-Van Heusen (NYSE: PVH) was upgraded to Buy from Neutral at BofA/Merrill.
• Reliant Energy (NYSE: RRI) was upgraded to Conviction Buy from Neutral at Goldman.

Analyst upgrades:

• FBR Capital upgraded Talbots (NYSE: TLB) to Outperform from Market Perform as it believes the company's inventory and SG&A control should help earnings and the stock's risk/reward is compelling at current levels. The firm raised its target on shares to $7 from $5.
• ThinkEquity upgraded Human Genome (NASDAQ: HGSI) to Buy from Accumulate to reflect higher assumptions for the company's Lupus treatment Benlysta. The firm raised its target on shares to $26 from $18.
• KeyBanc upgraded Parkway Properties (NYSE: PKY) to Buy from Hold based on valuation, improving fundamentals, and stable capital position. The firm has a $17 target on the stock.
• HSBC Holdings (NYSE: HBC) was upgraded to Overweight from Neutral at JPMorgan.
• BioScrip (NASDAQ: BIOS) was upgraded to Overweight from Neutral at Piper Jaffray.
• DISH Network (NASDAQ: DISH) was upgraded to Outperform from Neutral at Credit Suisse.

Analyst Upgrades

• Goldman upgraded Yum! Brands (NYSE: YUM) to Buy from Neutral on expectations business in the U.S. and China will improve in the second half of 2009. Goldman raised its target price on shares to $40 from $36.
• Canaccord upgraded Exco Resources (NYSE: XCO) to Buy from Speculative Buy citing the company's financial transactions to reduce debt. The firm, which has a $17 target on the stock, says Exco now has a stronger balance sheet, a greater geographic focus, and the ability to expedite drilling programs.
• ThinkEquity upgraded Shanda (NASDAQ: SNDA) to Accumulate from Source of Funds and raised its target to $60 from $50. The firm believes recent weakness on regulatory concerns is overdone and that Q2 estimates are conservative.
• Mack-Cali Realty (NYSE: CLI) was upgraded to Overweight from Equal Weight at Barclays.
• Marvel Entertainment (NYSE: MVL) was upgraded to Overweight from Neutral at JPMorgan.
• France Telecom (NYSE: FTE) was upgraded to Outperform from Underperform at Credit Suisse.

Surviving this recession is foremost on peoples' minds, but giving to charity is especially important in times like these. So how can you effectively give while preserving your net worth?

If you plan on liquidating any profitable, or taxable, positions in the stock market thanks to the current uptrend and also want to give to your favorite charity, the strategy outlined below is key to optimizing your gift, as well as your capital.

Though giving cash to causes is the most popular form of charity, desperate times call for creative measures, and any type of gift will be gladly accepted. By giving stock directly to charity, and bear in mind that the stock must be in your portfolio for one year or more as short-term capital gains are not applicable, you not only avoid capital gains taxes on your gains, but you can actually use the gift of your stock as a tax deduction. Hence, the cost of your gift is lower than giving cash directly. Think of it as an overall investment for yourself and the charity.